The European Union may pass a law that prohibits the import of medicines derived from sheep, goats and cattle, according to Jeffrey Trewhitt, vice president of communications for the Pharmaceutical Research and Manufacturers of America, Washington.
The European Union may pass a law that prohibits the import of medicines derived from sheep, goats and cattle, according to Jeffrey Trewhitt, vice president of communications for the Pharmaceutical Research and Manufacturers of America, Washington.
The ban, proposed because of concerns about Bovine Spongiform Encephalopathy, also known as Creutzfeldt-Jakob disease or mad cow disease, would affect roughly 85% of products exported to Europe by pharmaceutical companies in the United States. The potential economic impact of the ban is $4.5 billion in sales.
"This would affect any product that contained gelatin," Trewhitt explained. Gelatin, a common ingredient in drugs, is composed of the boiled skin, connective tissue and bones of animals, including those included in the proposed ban.
The European Union is the United States largest economic partner, largest investment partner and second-largest trading partner. Total U.S.-European Union trade was $270 billion in 1996. The two-way trade supports about six million jobs on both sides of the Atlantic.
European Union legislators originally planned to implement the prohibition on Jan. 1, but have postponed the date to April 1 in order to more closely analyze the risk posed by the products.
Risk analysis by PhRMA showed that the risk of acquiring mad cow disease by taking three gelatin capsules every day for one year was one in 100 billion.
The Clinton Administration is concerned about the proposal. American emissaries, representing national trade and commerce departments, were scheduling discussions with legislators in major European cities at press time. They will be discussing alternatives to the blanket ban, such as delegating the choice of embargoing certain products to individual member countries, or prohibiting only specific, high-risk drugs. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.